INmune Bio, Inc.
NASDAQ:INMBBiotechnology
+$0.15 today
- Market cap
- $50.25M
- Beta
- 0.98
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.56
Volume 0.09M
Average 0.68M
INMB Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
INmune Bio, Inc.NASDAQ: INMB
Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares (diluted) grows, but more slowly than its trailing trend
Q1 FY2026 weighted avg shares (diluted) of 26.59M shares rose 18.2% year over year, behind the +22.3% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +14.0% a year.
Context
- Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +18.2% toward the trailing-twelve-month pace of +22.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 26.59M USD
- Year-over-year change
- +33.3%
- 4-year CAGR
- +13.3%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 26.59M | +33.3% |
| FY2024 | 2024-12-31 | 19.94M | +10.9% |
| FY2023 | 2023-12-31 | 17.98M | +0.3% |
| FY2022 | 2022-12-31 | 17.93M | +11.1% |
| FY2021 | 2021-12-31 | 16.13M | — |
Weighted Avg Shares (Diluted) vs competitors
How INMB compares with its peers on the latest reported figures
- INMB's LTM Mar 2026 weighted avg shares (diluted) of 25.76M shares is the 3rd highest of the 4 companies compared; the peer median is 48.66M shares.
- Its year-over-year change of +22.3% is the 3rd highest of 4, against a peer median of +29.4%.
- Over three fiscal years its annual growth of +14.0% compares with a peer median of +17.5%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 71.88M | +964.0% | +171.3% | |
| LTM Mar 2026 | 48.66M | +29.4% | +17.5% | |
| LTM Mar 2026 | 25.76M | +22.3% | +14.0% | |
OKUROnKure Therapeutics, Inc. | LTM Mar 2026 | 13.55M | +1.4% | +0.4% |
| Peer median (excluding INMB) | 48.66M | +29.4% | +17.5% | |
Competitors are the stored peer set for INMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 181K | 374K | 155K | 14K | 50K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 181K | 374K | 155K | 14K | 50K |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 20.54M | 17.07M | 20.27M | 33.17M | 20.66M |
| Selling, General & Admin | 8.79M | 9.26M | 9.62M | 9.48M | 10.26M |
| Operating Expenses | 29.33M | 26.33M | 29.9M | 42.65M | 30.92M |
| Depreciation & Amortization | 29.15M | 25.95M | 29.74M | 553K | 84K |
| EBITDA | (1.19M) | (1.35M) | (267K) | (41.53M) | (45.85M) |
| EBITDA Margin | -655.8% | -360.4% | -172.3% | -296635.7% | -91698.0% |
| Operating Income | (29.15M) | (25.95M) | (29.74M) | (42.64M) | (30.87M) |
| Operating Margin | -16106.6% | -6938.8% | -19187.7% | -304535.7% | -61738.0% |
| Interest Income | 0 | 0 | 0 | 0 | 850K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (1.19M) | (1.35M) | (267K) | 553K | (15.06M) |
| Income Before Tax | (30.34M) | (27.3M) | (30.01M) | (42.08M) | (45.93M) |
| Pre-Tax Margin | -16762.4% | -7299.2% | -19360.0% | -300585.7% | -91866.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (30.34M) | (27.3M) | (30.01M) | (42.08M) | (45.93M) |
| Net Margin | -16762.4% | -7299.2% | -19360.0% | -300585.7% | -91866.0% |
| EPS (Basic) | (1.88) | (1.52) | (1.67) | (2.11) | (1.86) |
| EPS (Diluted) | (1.88) | (1.52) | (1.67) | (2.11) | (1.86) |
| Weighted Avg Shares | 16.13M | 17.93M | 17.98M | 19.94M | 26.59M |
| Weighted Avg Shares (Diluted) | 16.13M | 17.93M | 17.98M | 19.94M | 26.59M |
INmune Bio, Inc.
NASDAQ:INMB
Intrinsic Alpha fair value
Locked
Current Price
$1.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.